Adam Sutton

Adam is an associate principal scientist at Merck working in vaccine analytical research and development at the Pennsylvania site. Adam moved from Australia to the US at the start 2021 to work in vaccine development. Prior to working at Merck he completed a Masters at Western Sydney University in the Australian Center for Research On Separation Sciences (ACROSS) focused on CE of copolymers and carbohydrates. Adam then completed a PhD in the group of Prof. Emily Hilder at the University of South Australia on the topics of nanoparticle interactions with macromolecules using Affinity Capillary Electrophoresis (ACE). Currently Adam is the analytical lead at Merck for liposomal vaccine adjuvants and is a SME for CE, chromatography and NMR related methods in vaccine development.